These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 18820850)

  • 1. [Bisphosphonate-associated osteonecrosis of the jaw].
    Krauth MT; Fügl A; Gruber R
    Wien Klin Wochenschr; 2008; 120(15-16):467-76. PubMed ID: 18820850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bisphosphonates and osteonecrosis of the jaws].
    Urade M
    Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
    Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
    J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
    Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
    J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate-related osteonecrosis of the jaw: model and diagnosis with cone beam computerized tomography.
    Barragan-Adjemian C; Lausten L; Ang DB; Johnson M; Katz J; Bonewald LF
    Cells Tissues Organs; 2009; 189(1-4):284-8. PubMed ID: 18703870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteonecrosis of the jaw in patients on bisphosphonate treatment. review of literature with contribution of a case of multiple myeloma.
    Goranova-Marinova VS; Pechalova-Petrova PF; Goranov SG
    Folia Med (Plovdiv); 2009; 51(4):53-7. PubMed ID: 20232660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.
    Yarom N; Yahalom R; Shoshani Y; Hamed W; Regev E; Elad S
    Osteoporos Int; 2007 Oct; 18(10):1363-70. PubMed ID: 17598065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
    Gabbert TI; Hoffmeister B; Felsenberg D
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):749-58. PubMed ID: 25319961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiresorptive drug-related osteonecrosis of the jaw.
    Uyanne J; Calhoun CC; Le AD
    Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE; Umland EM
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate associated osteonecrosis of the jaw.
    Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Lentle B; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Mardini MA; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; Ste-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
    J Rheumatol; 2009 Mar; 36(3):478-90. PubMed ID: 19286860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
    O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC
    J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
    Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
    J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
    Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
    Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
    Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
    Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
    Abu-Id MH; Warnke PH; Gottschalk J; Springer I; Wiltfang J; Acil Y; Russo PA; Kreusch T
    J Craniomaxillofac Surg; 2008 Mar; 36(2):95-103. PubMed ID: 18234504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
    Van Poznak C; Estilo C
    Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis.
    Tubiana-Hulin M; Spielmann M; Roux C; Campone M; Zelek L; Gligorov J; Samson J; Lesclous P; Laredo JD; Namer M
    Crit Rev Oncol Hematol; 2009 Jul; 71(1):12-21. PubMed ID: 19070505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.